Biomarker evaluation in a randomized phase 2 study of MEHD7945A (MEHD) versus cetuximab (Cet) in ≥2 line recurrent/metastatic (R/M) squamous cell carcinomas of the head and neck (SCCHN) [MEHGAN]

被引：0
|
作者：
Pennel, Elicia [1 ]
Kapp, Amy V. [1 ]
Do, An [1 ]
Tam, Rachel [1 ]
Sumiyoshi, Teiko [1 ]
Marathe, Chaitra [1 ]
Sa, Susan [1 ]
Peale, Franklin [1 ]
Lackner, Mark [1 ]
Holden, Scott [1 ]
Seiwert, Tanguy [2 ]
Pirzkall, Andrea [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Chicago, Chicago, IL 60637 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-1553
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1553
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and, neck (SCCHN) refractory to first-line platinum-based therapies.
    Vermorken, JB
    Bourhis, J
    Trigo, J
    Kies, M
    Leon, X
    Mueser, M
    Amellal, N
    Schueler, A
    Baselga, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 501S - 501S
  • [22] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients (pts) with cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Bauman, J. E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn, Lara
    Ho, Alan Loh
    Eng, Juliana
    Michel, Loren S.
    Fetten, James Vincent
    Warner, Elizabeth
    Kriplani, Anuja
    Zhi, Wanqing Iris
    Ng, Kenneth K.
    Haque, Sofia
    Pfister, David G.
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME)
    Vermorken, J. B.
    Hitt, R.
    Geoffrois, L.
    Erfan, J.
    Kawecki, A.
    Zabolotnyy, D.
    Schueler, A.
    Knecht, R.
    Benasso, M.
    Kienzer, H.
    EJC SUPPLEMENTS, 2007, 5 (04): : 324 - 324
  • [25] Palliative chemotherapy (CT) with or without cetuximab (CTX) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An Indian retrospective analysis
    Bahl, A.
    Choudhary, P.
    Bhatia, K.
    Singhla, S.
    Shrivastava, G.
    Bal, J.
    Anand, A. K.
    Chaturvedi, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [26] A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Bossi, P.
    Miceli, R.
    Locati, L. D.
    Ferrari, D.
    Vecchio, S.
    Moretti, G.
    Denaro, N.
    Caponigro, F.
    Airoldi, M.
    Moro, C.
    Vaccher, E.
    Sponghini, A.
    Caldara, A.
    Rinaldi, G.
    Ferrau, F.
    Nole, F.
    Lo Vullo, S.
    Tettamanzi, F.
    Hollander, L.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2820 - 2826
  • [27] RESULTS OF TPEX (DOCETAXEL, CISPLATIN, CETUXIMAB) REGIMEN USE IN FIRST LINE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN A SINGLE INSTITUTION
    Even, C.
    Bobillot, B.
    Mayache-Badis, L.
    Ferrand, F. R.
    Lezghed, N.
    Bidault, F.
    Auperin, A.
    Temam, S.
    Janot, F.
    Schilf, A.
    Guigay, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [28] Phase 2 trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Obara, Grzegorz
    Sun, Jichao
    Loo, Deryk
    Bohac, Gerry C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Argiris, Athanassios
    Li, Shuli
    Savvides, Panayiotis
    Forastiere, Arlene A.
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF AFATINIB VERSUS CETUXIMAB IN RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
    Seiwert, T. Y.
    Fayette, J.
    Cupissol, D.
    DelCampo, J. M.
    Clement, P. M.
    Tourani, J. M.
    Degardin, M.
    Blackman, A. S.
    Cong, J.
    Solca, F.
    Ehrnrooth, E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 35
12345